筋痙縮市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、投与経路別、流通チャネル別、地域別、市場競争別、2020-2030F

筋痙縮の世界市場規模は2024年に41億1,000万米ドルで、予測期間には55億3,000万米ドルに達し、2030年までのCAGRは5.03%になると予測されています。

世界の筋痙縮市場は、より広範なヘルスケア産業の中でダイナミックに進化している分野であり、筋痙縮の複雑な病状に対処することに焦点を当てています。筋痙縮は不随意的な筋肉の収縮やこわばりを特徴とし、多発性硬化症、脳性麻痺、脊髄損傷などの神経疾患に起因することが多いです。この市場は、神経障害の有病率の増加、医療技術の進歩、高齢化人口の増加などを背景に、長年にわたって大きな成長と技術革新を遂げてきました。

市場促進要因

神経疾患の発生率の上昇

主な市場課題

高い治療費

主な市場動向

意識と教育の向上

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の筋痙縮市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤の種類別（バクロフェン、ボツリヌス毒素、ジアゼパム、ダントロレンナトリウム、その他）
  • 投与経路別（経口、筋肉内、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 薬剤の種類別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の筋痙縮市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤の種類別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の筋痙縮市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の筋痙縮市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の筋痙縮市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの筋痙縮市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の筋痙縮市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Muscle Spasticity Market was valued at USD 4.11 Billion in 2024 and is expected to reach USD 5.53 Billion in the forecast period with a CAGR of 5.03% through 2030. The global muscle spasticity market is a dynamic and evolving sector within the broader healthcare industry, focused on addressing the complex medical condition of muscle spasticity. Muscle spasticity is characterized by involuntary muscle contractions and stiffness, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries. This market has witnessed significant growth and innovation over the years, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and a growing aging population.

Key Market Drivers

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is a pivotal driver behind the burgeoning growth of the global muscle spasticity market. Neurological conditions such as multiple sclerosis (MS), cerebral palsy, spinal cord injuries, stroke, and Parkinson's disease frequently manifest with muscle spasticity, characterized by involuntary muscle contractions and stiffness that significantly impair patients' quality of life.

Multiple sclerosis, in particular, has seen a notable increase in prevalence. According to the World Health Organization (WHO), over 1.8 million people worldwide are affected by MS, with a higher incidence among young adults and females. This autoimmune disease affects the central nervous system and is a leading contributor to muscle spasticity. As the number of MS cases continues to rise, so does the demand for effective treatments to alleviate the debilitating symptoms associated with the condition. Pharmaceutical companies have responded by developing a range of medications aimed at providing relief and improving the daily lives of patients.

Key Market Challenges

High Treatment Costs

High treatment costs pose a significant hurdle in the global muscle spasticity market, impeding the accessibility of care for individuals grappling with this debilitating condition. Muscle spasticity, characterized by involuntary muscle contractions and stiffness, often results from neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. While treatment options have advanced, the soaring expenses associated with these therapies present a considerable challenge for both patients and healthcare systems. One of the primary issues driving the high treatment costs is the development and production of specialized medications and medical devices tailored for muscle spasticity management. Pharmaceutical companies invest heavily in research and development to create effective drugs that target the condition's symptoms and underlying causes. These innovative treatments, while offering hope for improved patient outcomes, often come with a substantial price tag, making them financially burdensome for many patients.

Key Market Trends

Increasing Awareness and Education

Increasing awareness and education have become instrumental in propelling the global muscle spasticity market forward. In recent years, concerted efforts by advocacy groups, healthcare organizations, and pharmaceutical companies have led to a significant uptick in public understanding and recognition of this debilitating condition. Muscle spasticity, a common symptom in neurological disorders like multiple sclerosis, spinal cord injuries, and stroke, was often overlooked or misunderstood in the past. However, with increased awareness campaigns and educational initiatives, both patients and healthcare providers are now more informed about its prevalence, symptoms, and available treatment options.

Key Market Players

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Spasticity Market, By Drug Type:

• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

Muscle Spasticity Market, By Route of Administration:

• Oral
• Intramuscular
• Others

Muscle Spasticity Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Muscle Spasticity Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.

Available Customizations:

Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Muscle Spasticity Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
  • 4.2.2. By Route of Administration (Oral, Intramuscular, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Muscle Spasticity Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Muscle Spasticity Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Muscle Spasticity Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Muscle Spasticity Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Muscle Spasticity Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Muscle Spasticity Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Muscle Spasticity Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Muscle Spasticity Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Muscle Spasticity Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Muscle Spasticity Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Muscle Spasticity Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Muscle Spasticity Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Muscle Spasticity Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Muscle Spasticity Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Muscle Spasticity Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Muscle Spasticity Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Muscle Spasticity Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Muscle Spasticity Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Muscle Spasticity Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Muscle Spasticity Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Muscle Spasticity Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Muscle Spasticity Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Muscle Spasticity Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Muscle Spasticity Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Muscle Spasticity Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Ipsen Pharma
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Allergan
• 14.3. Acorda Therapeutics, Inc.
• 14.4. Merz Pharma
• 14.5. Novartis AG
• 14.6. Beximco Pharmaceuticals Ltd.
• 14.7. Zydus Cadila
• 14.8. Porex Corporation
• 14.9. Teva Pharmaceutical Industries Ltd
• 14.10. Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer